May 28, 2024
Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024
May 14, 2024
Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences
May 02, 2024
Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
May 01, 2024
Alkermes plc Reports First Quarter 2024 Financial Results
Apr 24, 2024
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
Apr 17, 2024
Alkermes to Report First Quarter Financial Results on May 1, 2024
Apr 09, 2024
Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
Apr 08, 2024
Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society
Feb 15, 2024
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024
Feb 08, 2024
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024
Jan 03, 2024
Alkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Jan 03, 2024
Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI® (olanzapine and samidorphan)
Feb 18, 2021
Alkermes to Take Part in SVB Leerink 10th Annual Global Healthcare Conference
Feb 04, 2021
Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2020 Financial Results
Jan 14, 2021
NIDA-Funded Study Evaluating Extended-Release Injectable Naltrexone Plus Bupropion for the Treatment of Methamphetamine Use Disorder Published in New England Journal of Medicine
Jan 06, 2021
Alkermes to Present at the 39th Annual J.P. Morgan Healthcare Conference
Dec 29, 2020
FDA Accepts Alkermes' Resubmission of New Drug Application for ALKS 3831
Dec 10, 2020
Alkermes Announces Strategic Value Enhancement Plan and Continued Board Refreshment
Nov 17, 2020
Alkermes Receives FDA Complete Response Letter Related to ALKS 3831 Manufacturing Records Review
Nov 09, 2020
Alkermes Presents New Data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting